INTELLIGENT NANOMEDICINE INTEGRATING DIAGNOSIS AND THERAPY

INTELLIGENT NANOMEDICINE INTEGRATING DIAGNOSIS AND THERAPY

UCLA Technology Available For Licensing

BACKGROUND: With the rapid advances of modern pharmacology, effective drugs have been discovered for many diseases; however, most of those drugs have undesirable side effects due to their inability to distinguish between diseased and healthy cells. For instance, chemotherapy that is commonly used for treatment of cancer does not only target the cancer cells, but also damages healthy cells.

INNOVATION: UCLA researchers have invented an intelligent nanomedicine that is only activated in sick cells due to its dual integration of diagnostic and therapeutic functions. The diagnosis is continuously performed through the recognition of biomarkers for a specific disease. The nanomedicine changes its confirmation when the diagnostic result changes, either activating or deactivating the drug. Thus, the nanomedicine can intelligently adjust its dosage according to the amount of biomarker present.

POTENTIAL APPLICATIONS

The technology can be used to selectively target drugs to their intended sites of action.

ADVANTAGES

Cytotoxicity of healthy cells can be reduced.
The nanomedicine can be easily diversified.
It can be directly applied to many current therapies.

Reference: UCLA Case No. 2004-675 PCT Application: PCT/US05/024377

For additional technical details and current licensing
availability, please contact the following UCLA office:

UCLA Office of Intellectual Property

11000 Kinross Avenue, Suite #200

Los Angeles, CA 90095-7231

Tel: 310-794-0558 Fax: 310-794-0638

email: ncd@research.ucla.edu

NCD URL: http://www.research.ucla.edu/tech/ucla04-675.htm

UCLA Technologies Available for Licensing
http://www.research.ucla.edu/oipa/industry

keywords: therapuetic diagnostic uclancd ucla technologies intellectual property patents technology transfer invention business card